Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.177.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.164NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-4751.81US
B.1.1.164NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
B.1.250NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.250NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.63NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.177.63NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.27NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.27NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.23NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-18756.6US
B.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.130NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.130NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.44NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.44NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.362.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.362.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.48NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.177.48NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.9NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.36.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.520NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.520NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.38NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.36.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.50 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.50 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.266NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.266NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.253NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.253NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.305NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.305NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AA.6NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AA.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.241NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.241NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.33NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.177.33NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.326NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.326NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.255NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.255NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.303NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.303NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AA.7NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AA.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.173NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.173NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.213NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used